KRAS and endometrium neoplasm: Similarly, in endometrial tumors, KRAS G13D mutated tumors showed a higher prevalence of NF1 and PTEN alterations compared to KRAS G12D (NF1: 14.0% vs. 6.1%, FDR p = 0.005; PTEN: 70.6% vs. 55.1%, p = 0.0006, respectively).